BioCentury
ARTICLE | Clinical News

Lusduna regulatory update

November 17, 2016 2:33 PM UTC

EMA's CHMP recommended approval of Lusduna from Merck to treat diabetes in patients ages ≥2. The product is a biosimilar of Lantus insulin glargine, a synthetic sustained-release subcutaneous insulin analog from Sanofi (Euronext:SAN; NYSE:SNY, Paris, France). It is under FDA review to treat Type I and Type II diabetes (see BioCentury, Aug. 8)...